Cerevel Therapeutics Holdings Inc (CERE) Stock
CERE is no longer traded. Cerevel Therapeutics Holdings was acquired by AbbVie (ABBV) on August 1, 2024.
Each CERE share was exchanged for $45.00 in cash. Prices on this page are historical; the last trade was July 31, 2024 at $44.96.
See AbbVie (ABBV) stock →Cerevel Therapeutics Holdings stock price history
CERE final trading statistics
- Final close
- $44.96
- Final trading day
- Jul 31, 2024
- Market cap at delisting
- $8.19B
- Shares outstanding
- 182.20M
- Final 52-week range
- $19.59 – $44.99
- Avg. volume (final 3 mo.)
- 2,056,590
- All-time high (split-adj.)
- $44.96 · Jul 2024
- All-time low (split-adj.)
- $9.82 · Nov 2020
- Return since IPO
- +277.8%
- Beta
- 1.41
- Book value / share
- $3.10
- Price / book
- 14.49
Cerevel Therapeutics Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$432.8M | -$2.67 |
| FY2022 | $0.00 | -$351.5M | -$2.33 |
| FY2021 | $0.00 | -$222.4M | -$1.65 |
| FY2020 | $0.00 | -$152.1M | -$5.77 |
| FY2019 | $0.00 | -$128.4M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.
Cerevel Therapeutics Holdings stock FAQ
What happened to Cerevel Therapeutics Holdings stock?
Cerevel Therapeutics Holdings was acquired by AbbVie (ABBV) on August 1, 2024. Shareholders received $45.00 in cash for each share. CERE stock stopped trading on the Nasdaq, with a final close of $44.96 on July 31, 2024.
What did Cerevel Therapeutics Holdings shareholders receive?
Each CERE share was converted into $45.00 in cash. The deal was valued at about $8.7 billion.
Is CERE stock still trading?
No. CERE was delisted from the Nasdaq on August 1, 2024 and no longer trades on a U.S. exchange.
What was the last price of CERE stock?
CERE closed at $44.96 on its final trading day, July 31, 2024, for a market value of about $8.19B.
What were Cerevel Therapeutics Holdings's revenue and earnings in its last full fiscal year?
Cerevel Therapeutics Holdings reported revenue of $0.00 and net income of -$432.8M in fiscal 2023, its last full year as a public company.
When did Cerevel Therapeutics Holdings go public?
Cerevel Therapeutics Holdings Inc stock began trading on October 28, 2020.